Dabrafenib–trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer
Fumihiro Kashizaki, Arihito Tanaka, Shigeaki Hattori, Shunsuke Sugimoto
Topics & Concepts
TrametinibDabrafenibMEK inhibitorLung cancerCancer researchMedicineTargeted therapyCancerOncologyMAPK/ERK pathwayInternal medicineMelanomaVemurafenibKinaseBiologyGeneticsMetastatic melanomaMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy